Denali Therapeutics Inc. (NASDAQ:DNLI) Stock Holdings Lessened by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. lessened its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 37.3% in the second quarter, Holdings Channel.com reports. The fund owned 16,753 shares of the company’s stock after selling 9,968 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in Denali Therapeutics were worth $389,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of DNLI. Vanguard Group Inc. boosted its position in shares of Denali Therapeutics by 1.2% in the first quarter. Vanguard Group Inc. now owns 10,968,293 shares of the company’s stock worth $225,069,000 after buying an additional 133,810 shares during the period. Capital Research Global Investors increased its holdings in shares of Denali Therapeutics by 107.9% in the 1st quarter. Capital Research Global Investors now owns 6,049,957 shares of the company’s stock valued at $124,145,000 after purchasing an additional 3,140,429 shares during the period. Baker BROS. Advisors LP lifted its position in shares of Denali Therapeutics by 43.1% in the first quarter. Baker BROS. Advisors LP now owns 3,731,695 shares of the company’s stock worth $76,574,000 after purchasing an additional 1,124,499 shares in the last quarter. Norges Bank purchased a new position in Denali Therapeutics during the fourth quarter valued at approximately $24,736,000. Finally, Principal Financial Group Inc. increased its stake in Denali Therapeutics by 4.5% in the 1st quarter. Principal Financial Group Inc. now owns 1,122,536 shares of the company’s stock valued at $23,034,000 after buying an additional 48,832 shares during the period. 92.92% of the stock is owned by institutional investors.

Insider Activity at Denali Therapeutics

In related news, Director Steve E. Krognes sold 30,000 shares of the business’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $22.12, for a total transaction of $663,600.00. Following the transaction, the director now directly owns 34,404 shares in the company, valued at $761,016.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, Director Jennifer E. Cook sold 1,458 shares of the business’s stock in a transaction that occurred on Thursday, June 6th. The shares were sold at an average price of $21.73, for a total transaction of $31,682.34. Following the completion of the sale, the director now directly owns 20,038 shares of the company’s stock, valued at $435,425.74. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Steve E. Krognes sold 30,000 shares of the firm’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $22.12, for a total value of $663,600.00. Following the completion of the transaction, the director now owns 34,404 shares in the company, valued at $761,016.48. The disclosure for this sale can be found here. Insiders sold a total of 32,146 shares of company stock worth $710,274 in the last ninety days. 7.90% of the stock is currently owned by insiders.

Denali Therapeutics Price Performance

Shares of DNLI stock traded down $0.50 during trading on Tuesday, reaching $23.45. The company had a trading volume of 72,435 shares, compared to its average volume of 1,149,578. The firm’s 50 day simple moving average is $22.44 and its two-hundred day simple moving average is $20.08. Denali Therapeutics Inc. has a one year low of $14.56 and a one year high of $25.24. The company has a market capitalization of $3.34 billion, a PE ratio of -26.33 and a beta of 1.40.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings results on Thursday, August 1st. The company reported ($0.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.09. The business had revenue of $1.00 million during the quarter, compared to analyst estimates of $10.00 million. During the same period in the prior year, the business posted $1.30 earnings per share. The company’s revenue for the quarter was down 99.7% compared to the same quarter last year. Analysts forecast that Denali Therapeutics Inc. will post -2.77 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently commented on DNLI. HC Wainwright restated a “buy” rating and set a $90.00 price target on shares of Denali Therapeutics in a report on Thursday, August 15th. Citigroup lifted their price objective on Denali Therapeutics from $26.00 to $32.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. JPMorgan Chase & Co. upped their target price on Denali Therapeutics from $28.00 to $29.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 10th. Wedbush reduced their price target on Denali Therapeutics from $30.00 to $26.00 and set an “outperform” rating for the company in a report on Friday, August 2nd. Finally, Stifel Nicolaus lowered their price target on Denali Therapeutics from $26.00 to $22.00 and set a “hold” rating for the company in a research note on Wednesday, May 8th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $39.33.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.